Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397485 | 0.89 | EGFR (0.47) | EGFRPIK3CDPIK3CATRPV1 | |
| SCHEMBL18713976 | 0.87 | PIK3CA (0.54) | EGFRPIK3CDPIK3CAFGFR4AR | |
| SCHEMBL7117073 | 0.87 | TLR8 (0.48) | EGFRTRPV1 | |
| SCHEMBL9971269 | 0.86 | EGFR (0.51) | EGFRCNR1CNR2TDO2TRPV1 | |
| SCHEMBL9776814 | 0.86 | EGFR (0.55) | EGFRPIK3CDPIK3CAFGFR4AR | |
| SCHEMBL30918007 | 0.86 | EGFR (0.55) | EGFRPIK3CDPIK3CAFGFR4AR | |
| SCHEMBL19338494 | 0.83 | EGFR (0.51) | EGFRPIK3CDPIK3CAFGFR4AR | |
| SCHEMBL27314267 | 0.83 | EGFR (0.51) | EGFRPIK3CDPIK3CAFGFR4AR | |
| SCHEMBL9968621 | 0.81 | EGFR (0.54) | EGFRPIK3CDPIK3CAFGFR4AR | |
| SCHEMBL30406139 | 0.81 | EGFR (0.54) | EGFRPIK3CDPIK3CAFGFR4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104803927-B | Chalcone analog of the base containing 2 methyl, 4 oxoquinazolin 6 and its production and use | 首都师范大学 | 2017-11-07 | — | — | CN | disclosed |
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE4A, PDE12 | EGFR 4771/4885PIK3CD 432/4885PIK3CA 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.